TY - JOUR
T1 - T-cell prolymphocytic leukemia
T2 - A single-institution experience
AU - Ravandi, Farhad
AU - O'Brien, Susan
AU - Jones, Dan
AU - Lerner, Susan
AU - Faderl, Stefan
AU - Ferrajoli, Alessandra
AU - Wierda, William
AU - Garcia-Manero, Guillermo
AU - Thomas, Deborah
AU - Koller, Charles
AU - Verstovsek, Srdan
AU - Giles, Francis
AU - Cortes, Jorge
AU - Herling, Marco
AU - Kantarjian, Hagop
AU - Keating, Michael
PY - 2005/11
Y1 - 2005/11
N2 - Background: T-cell prolymphocytic leukemia is an uncommon, aggressive, mature T-cell leukemia characterized by proliferation of T-cell lymphocytes. The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias. Patients and methods: The clinical,pathologic, and cytogenetic features of 57 patients with T-PLL who were evaluated at the Department of Leukemia, M. D. Anderson Cancer Center (MDACC) from 1986 to 2004 were examined. Results: The most common cytogenetic abnormality was inv(14) (q11;q32), which was present in 7 patients. In all 7 patients, this abnormality was associated with other chromosomal aberrations. Patients treated with alemtuzumab at MDACC had a significantly better response rate (P = 0.02) and survival rate (P = 0.002). There were no significant differences in survival based on Tcl-1 expression or different patterns of CD4 and CD8 expression. Conclusion: Treatment with alemtuzumab results in higher response rates and a better survival rate in patients with T-cell prolymphocytic leukemia.
AB - Background: T-cell prolymphocytic leukemia is an uncommon, aggressive, mature T-cell leukemia characterized by proliferation of T-cell lymphocytes. The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias. Patients and methods: The clinical,pathologic, and cytogenetic features of 57 patients with T-PLL who were evaluated at the Department of Leukemia, M. D. Anderson Cancer Center (MDACC) from 1986 to 2004 were examined. Results: The most common cytogenetic abnormality was inv(14) (q11;q32), which was present in 7 patients. In all 7 patients, this abnormality was associated with other chromosomal aberrations. Patients treated with alemtuzumab at MDACC had a significantly better response rate (P = 0.02) and survival rate (P = 0.002). There were no significant differences in survival based on Tcl-1 expression or different patterns of CD4 and CD8 expression. Conclusion: Treatment with alemtuzumab results in higher response rates and a better survival rate in patients with T-cell prolymphocytic leukemia.
KW - CD52 antigen
KW - Deoxycoformycin
KW - Fludarabine
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=33644873209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644873209&partnerID=8YFLogxK
U2 - 10.3816/CLM.2005.n.051
DO - 10.3816/CLM.2005.n.051
M3 - Article
C2 - 16354329
AN - SCOPUS:33644873209
SN - 1557-9190
VL - 6
SP - 234
EP - 239
JO - Clinical Lymphoma and Myeloma
JF - Clinical Lymphoma and Myeloma
IS - 3
ER -
